SGT-501

About Solid Biosciences

Solid Biosciences is a publicly traded biotech focused on advancing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases, including lead program SGT-003 for Duchenne muscular dystrophy. The company's strategy is dual-pronged: progressing specific therapeutic candidates through clinical development while investing in proprietary platform technologies, such as libraries of genetic regulators, to enhance gene therapy delivery and efficacy broadly. With a founding story rooted in personal patient experience, Solid aims to improve daily life outcomes by uniting expertise in science, technology, and disease management.

Therapeutic Areas